Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
DPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing DPH Oxidase or Rel D(P)H Oxidase or NOX4 or EC 1.6.3.) - Overview
DPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing DPH Oxidase or Rel D(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
DPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing DPH Oxidase or Rel D(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
DPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing DPH Oxidase or Rel D(P)H Oxidase or NOX4 or EC 1.6.3.) - Companies Involved in Therapeutics Development
GenKyoTex SA
Glucox Biotech AB
New Amsterdam Sciences Inc
OliPass Corporation
DPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing DPH Oxidase or Rel D(P)H Oxidase or NOX4 or EC 1.6.3.) - Drug Profiles
Antisense Oligonucleotides to Inhibit NOX4 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setaxib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX-4 for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing DPH Oxidase or Rel D(P)H Oxidase or NOX4 or EC 1.6.3.) - Dormant Products
DPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing DPH Oxidase or Rel D(P)H Oxidase or NOX4 or EC 1.6.3.) - Discontinued Products
DPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing DPH Oxidase or Rel D(P)H Oxidase or NOX4 or EC 1.6.3.) - Product Development Milestones
Featured News & Press Releases
Dec 03, 2019: Genkyotex reports progress of Setaxib Phase 2 investigator initiated trials
Jul 25, 2019: Genkyotex announces positive post-hoc alysis of PBC phase 2 trial and reports cash position at June 30, 2019
Jul 24, 2019: Genkyotex conference call for post-hoc alysis of Setaxib (GKT831) PBC Ph2 trial and business update
Jul 22, 2019: The WHO recognizes NOX inhibitors as new therapeutic class and approves setaxib for GKT831
Jul 18, 2019: Genkyotex to launch Phase II pulmory fibrosis trial in US
Jul 01, 2019: Genkyotex’s GKT831 prevents multiple complications of portal hypertension in preclinical model
Jun 24, 2019: Genkyotex announces positive fil results of GKT831 trial in PBC
May 23, 2019: Genkyotex invites shareholders to Annual General Meeting on June 13, 2019
May 21, 2019: Preclinical study of GKT831 shows rapid regression of cholestatic fibrosis in model of advanced liver fibrosis
May 02, 2019: Genkyotex reports mixed efficacy Phase II data for PBC drug
Apr 08, 2019: Genkyotex to present updated interim results from Phase 2 trial of GKT831 in Primary Biliary Cholongitis at 2019 EASL Intertiol Liver Congress (ILC)
Mar 11, 2019: Genkyotex announces completion of 24-week treatment period of its phase 2 yrial with GKT831 in primary biliary cholangitis
Feb 11, 2019: Genkyotex Announces Award of Grant from Cancer Research UK to Academic Partner to Further Develop NOX Research in Oncology
Jan 25, 2019: Genkyotex provides update on its primary biliary cholangitis drug candidate GKT831
Dec 19, 2018: Genkyotex announces an extraordiry shareholders meeting to be held on January 24, 2019 at 10 am and confirms the key development milestone for GKT831 in PBC
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by GenKyoTex SA, H2 2019
Pipeline by Glucox Biotech AB, H2 2019
Pipeline by New Amsterdam Sciences Inc, H2 2019
Pipeline by OliPass Corporation, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019